Connect with us

Business

Business Confidence of Germany Goes Up Unexpectedly

Published

on

Germany’s business confidence unpredictably increased from the least in two-and-a-half years in Nov, indicating the largest economy of Europe may recover strength to a good extent.

The IFO institute based in Munich revealed its business climate index, based on a survey of 7,000 executives, which rose to 101.4 this month from 100 in the previous month. The economists forecasted a fall to 99.5, as per the average of 48 predictions in a survey conducted by Bloomberg. The business confidence of France rose from the least in over 3 years this month, according to a separate report.

The growth of Germany slowed lesser than the predictions of economists in the 3rd quarter even as the Euro region crisis continued, and the largest trading partner in the nation, went into recession as the stance for the global economy weakened. German manufacturing slowed down in this month, adding to indications of an economic recession in the 4th quarter, while the recession may not last too long.

The Stoxx Europe 600 Index came down slightly, while the euro gained for a 5th consecutive day, trading at $1.2915.

German Recession

The expectations of Ifo’s measure of executives increased from October’s 93.2 to 95.2 this month, while a measure of the present condition increased to 108.1 from a reworked 107.2.

The growth of Germany slowed down to 0.2% in Q3 from 0.3% in Q2, as confirmed by Federal Statistics Office today. Construction, exports, and household spending were the key contributors to growth, while company investment in machinery and plant and inventories deducted from it.

The consumer confidence in Germany may increase to a 5-year high this month, as per GfK (a market research firm), as increasing wages and joblessness near a 2-decade low prevail over economic concerns. The economy will expand 0.8% in 2012 and 2013, according to the predictions of the European Commission. In contrast, it forecasts a 0.4% contraction in the euro region in 2012 and growth of around 0.1% next year.

Growth Slowdown

London-based Daiwa International’s economist, Tobias Blattner told that though they were anticipating the economy to slowdown in the 4th quarter, situations are likely to improve next year. According to him, it is likely to be a growth dip rather than German recession.

Elsewhere in the Euro region, economies are also indicating few signals of recovery. The business confidence of France rose in this month after Francois Hollande (president) revealed a cut in payroll tax for firms that will come into effect next year. A measure of sentiment amongst factory executives increased from 85 in last month to 88 this month, as stated by national statistics office Insee.

Business

Top 3 Gainers: Zynga (NASDAQ:ZNGA), Eros International (NYSE:EROS), Borqs Technologies’ (BRQS)

Published

on

By

Zynga (NASDAQ:ZNGA) is up 2.5% after Benchmark reiterated its Buy rating in a look-ahead at Q2 earnings. The firm’s expecting a beat and solid guidance for Q3, and it’s raising its guidance for the fiscal year.

Tailwinds from the pandemic won’t dissipate easily, Benchmark suggests, and the videogame maker’s acquisition of Peak (and with it new “forever franchises” in Toon Blast and Toy Blast) will drive audience, bookings, margins and free cash flow, it says. The firm has an $11 price target, now implying 14% upside.

Eros International (NYSE:EROS) is up 5.8% today, making up the last week’s lost ground, after news that its streaming service Eros Now is partnering with Sony India (SNE +2.3%).

That will mean Eros Now’s app is pre-installed on selected Sony smart televisions in India, along with availability on a large base of existing models (Bravia E series and newer).

The country over the past year has seen a 25% growth in demand for smart TVs, fueled by overall industry growth of 15%, to a record 15M units/year.

Borqs Technologies’ (BRQS) personal safety tracker sees strong market with increased orders from the electronics retail chain in the US.

The boost in product demand comes ahead coronavirus pandemic that provides company to expect delivery of 250K units this year. It reflects over 3x the volume delivered in 2019, the year of its launch.

Borqs’ mobile personal safety devices designed particularly for senior citizens come with panic button, location tracking, and fall detection.

Continue Reading

Biotech

Biotech movers: Pfizer Inc. (PFE), Celgene Corporation (CELG)

Published

on

Pfizer Inc. (PFE) said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.

Pfizer, in a regulatory filing, said it would be producing records in response to the civil investigative demand from the U.S. Attorney’s office for the Southern District of New York.

Why ASDN Could Massively Outperform PFE in 2019

Meridian, a unit of Pfizer that manufactures EpiPen injectors used to deliver an emergency allergy antidote, has been hit by a series of manufacturing problems in recent years. Mylan NV, which markets EpiPens, has recalled tens of thousands of the devices after complaints that some had failed to activate.

Bristol-Myers Squibb has been meeting with shareholders in Boston and New York over the last two weeks to try to salvage its $74 billion purchase of cancer drugmaker Celgene Corporation (CELG), the biggest acquisition announced so far this year.

Why Investors Are Calling ASDN the CELG of the Sky!

The deal, announced in January, was hard sell to Bristol shareholders from the start. The acquisition adds about $32 billion in fresh debt to Bristol’s balance sheet while assuming $20 billion in Celgene’s debt, the companies said at the time. After factoring in debt, the acquisition was the largest health-care deal on record, according to data compiled by Refinitiv.

Now, hedge funds Wellington Management and Starboard Value say the deal doesn’t sit well with them. Bristol has sent executives to New York to meet with institutional investors several times over the last two weeks and met with investors in Boston on Wednesday and Thursday, according to a person who briefed on the meetings.

Bristol-Myers declined to comment.

Continue Reading

Biotech

Big Losers: Corbus Pharmaceuticals Holdings, Inc. (CRBP), Petróleo Brasileiro S.A. – Petrobras (PBR)

Published

on

Corbus Pharmaceuticals Holdings, Inc. (CRBP)’s shares slumped as much as 16% to $6.94 on huge volume. The stock has been showing intense sell off suddenly after a bearish article on seekingalph.com by Alpha Exposure.

The article stated that Corbus has ties to investors convicted of or alleged to have committed securities fraud. We believe lenabasum has failed its major trials in SSc and CF. Lenabasum was also denied Breakthrough Therapy Designation in SSc. We believe lenabasum will fail in its pivotal SSc and Phase 2b CF trials. We are short Corbus with a price target of $0.50.

Wow the future of Autonomous flight is finally here with the launch of ASDN passenger drone Elroy

Petróleo Brasileiro S.A. – Petrobras (PBR) is expanding its ambitious divestment program and has “bold” plans for sales, the Brazilian state-run oil company’s chief executive said after the firm posted its first annual profit in five years.

On a conference call with analysts to discuss fourth-quarter results, CEO Roberto Castello Branco said selling non-core assets will be key to deleveraging.

Petrobras, as the company is known, can reduce its ratio of net debt to earnings before interest, taxes, depreciation and amortization, or EBITDA, to 1.5 or even to 1, he added.

The University of Chicago-educated CEO, who took the reins in early January, has long been vocal about the need to slim down the sprawling firm and focus on core activities such as exploration and production. Thursday’s comments were some of his most assertive on the matter.

Why Investors Are Calling ASDN the TPC of the Sky!

Continue Reading
Advertisement

Trending